CMP-CPS-001
Sponsors
Camp4 Therapeutics Corp., CAMP4 Therapeutics Corporation
Conditions
Healthy VolunteersOTC DeficiencyUrea cycle disorders (UCD)
Phase 1
Study of CMP-CPS-001 in Healthy Volunteers and Participants With Abnormal Heterozygous OTC Genotype
Active, not recruitingNCT06247670
Start: 2024-02-05End: 2027-12-01Target: 120Updated: 2026-04-22
A Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase 1 Study of CMP-CPS-001 in Healthy Volunteers and Participants with Abnormal Heterozygous Ornithine Transcarbamylase (OTC) Genotype
Not yet recruitingCTIS2025-520882-37-00
Target: 12Updated: 2025-08-09